Novo Nordisk Shares Drop Amid Revised 2025 Outlook and Growth Concerns
Novo Nordisk's stock declined after cutting its sales forecast due to slower growth in its diabetes and obesity treatments, amid increased competition from Eli Lilly and efforts to expand market presence, including potential acquisition of Metsera and development of an oral GLP-1 drug.